DE602005017373D1 - Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten - Google Patents
Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeitenInfo
- Publication number
- DE602005017373D1 DE602005017373D1 DE602005017373T DE602005017373T DE602005017373D1 DE 602005017373 D1 DE602005017373 D1 DE 602005017373D1 DE 602005017373 T DE602005017373 T DE 602005017373T DE 602005017373 T DE602005017373 T DE 602005017373T DE 602005017373 D1 DE602005017373 D1 DE 602005017373D1
- Authority
- DE
- Germany
- Prior art keywords
- gluco
- compounds
- treating schizophrenia
- regulatory conditions
- regulatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002039 glucoregulatory effect Effects 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55845104P | 2004-04-01 | 2004-04-01 | |
| PCT/US2005/011107 WO2005097122A2 (en) | 2004-04-01 | 2005-04-01 | Method of treating schizophrenia and/or glucoregulatory abnormalities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602005017373D1 true DE602005017373D1 (de) | 2009-12-10 |
Family
ID=34978926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602005017373T Expired - Lifetime DE602005017373D1 (de) | 2004-04-01 | 2005-04-01 | Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20070129403A1 (https=) |
| EP (2) | EP1734959B1 (https=) |
| JP (1) | JP2007531730A (https=) |
| KR (1) | KR20070010161A (https=) |
| CN (1) | CN1946399A (https=) |
| AR (1) | AR048197A1 (https=) |
| AT (1) | ATE446754T1 (https=) |
| AU (1) | AU2005231446A1 (https=) |
| BR (1) | BRPI0509512A (https=) |
| CA (1) | CA2561162A1 (https=) |
| CL (1) | CL2009001605A1 (https=) |
| CY (1) | CY1109734T1 (https=) |
| DE (1) | DE602005017373D1 (https=) |
| DK (1) | DK1734959T3 (https=) |
| DO (1) | DOP2005000050A (https=) |
| ES (1) | ES2334241T3 (https=) |
| GT (1) | GT200500063A (https=) |
| IL (1) | IL178168A0 (https=) |
| MX (1) | MXPA06011222A (https=) |
| PA (1) | PA8628601A1 (https=) |
| PL (1) | PL1734959T3 (https=) |
| PT (1) | PT1734959E (https=) |
| SI (1) | SI1734959T1 (https=) |
| SV (1) | SV2006002069A (https=) |
| TW (1) | TW200602040A (https=) |
| WO (1) | WO2005097122A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| AR056968A1 (es) | 2005-04-11 | 2007-11-07 | Xenon Pharmaceuticals Inc | Compuestos espiro-oxindol y composiciones farmacéuticas |
| US20110294842A9 (en) * | 2006-10-12 | 2011-12-01 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| WO2008060789A2 (en) | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| CA2741024A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| JO3032B1 (ar) | 2008-10-17 | 2016-09-05 | Xenon Pharmaceuticals Inc | مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية. |
| WO2010068750A2 (en) * | 2008-12-11 | 2010-06-17 | Board Of Trustees Of Leland Stanford Junior University | Compositons and method for treatment of mood and cognitive impairments |
| EP2437744B1 (en) * | 2009-06-03 | 2015-06-03 | Marquette University | Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| KR20120099429A (ko) | 2009-10-14 | 2012-09-10 | 제논 파마슈티칼스 인크. | 스피로-옥스인돌 화합물의 합성 방법 |
| WO2011106729A2 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CN103512972A (zh) * | 2013-07-29 | 2014-01-15 | 上海交通大学 | 精神分裂症的生物标志物及其使用方法和应用 |
| WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
| KR101759122B1 (ko) | 2015-08-07 | 2017-07-18 | 계명대학교 산학협력단 | 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물 |
| EP4516356A3 (en) | 2016-08-24 | 2025-05-14 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
| EP3941352A1 (en) | 2019-03-19 | 2022-01-26 | Cambridge Cognition Limited | Method and uses of diagnosing and recommending treatment for a psychotic disorder |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0287982B1 (en) * | 1987-04-24 | 1994-12-07 | Hoechst-Roussel Pharmaceuticals Incorporated | N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments |
| US4970218A (en) | 1987-04-24 | 1990-11-13 | Hoechst-Roussel Pharmaceuticals Inc. | N-(pyridinyl)-1H-indol-1-amines |
| US4880822A (en) * | 1987-04-24 | 1989-11-14 | Hoechst-Roussel Pharmaceuticals, Inc. | N-(pyridinyl)-1H-indol-1-amines |
| US5102891A (en) * | 1990-07-23 | 1992-04-07 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates |
| US5214038A (en) * | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| US5356910A (en) * | 1993-07-19 | 1994-10-18 | Hoechst-Roussel Pharmaceuticals Inc. | Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder |
| DE69621617T2 (de) * | 1995-07-27 | 2003-01-02 | Aventis Pharmaceuticals Inc., Bridgewater | Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva |
| EP0876379A1 (en) | 1996-01-17 | 1998-11-11 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| RU2215004C2 (ru) | 1997-07-16 | 2003-10-27 | Ново Нордиск А/С | Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата |
| GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
-
2005
- 2005-03-22 GT GT200500063A patent/GT200500063A/es unknown
- 2005-03-30 DO DO2005000050A patent/DOP2005000050A/es unknown
- 2005-03-31 AR ARP050101275A patent/AR048197A1/es not_active Application Discontinuation
- 2005-04-01 PT PT05732721T patent/PT1734959E/pt unknown
- 2005-04-01 KR KR1020067022972A patent/KR20070010161A/ko not_active Ceased
- 2005-04-01 ES ES05732721T patent/ES2334241T3/es not_active Expired - Lifetime
- 2005-04-01 SI SI200530883T patent/SI1734959T1/sl unknown
- 2005-04-01 SV SV2005002069A patent/SV2006002069A/es unknown
- 2005-04-01 PL PL05732721T patent/PL1734959T3/pl unknown
- 2005-04-01 EP EP05732721A patent/EP1734959B1/en not_active Expired - Lifetime
- 2005-04-01 MX MXPA06011222A patent/MXPA06011222A/es active IP Right Grant
- 2005-04-01 JP JP2007506313A patent/JP2007531730A/ja not_active Abandoned
- 2005-04-01 PA PA20058628601A patent/PA8628601A1/es unknown
- 2005-04-01 EP EP09012248A patent/EP2138176A1/en not_active Withdrawn
- 2005-04-01 AT AT05732721T patent/ATE446754T1/de not_active IP Right Cessation
- 2005-04-01 AU AU2005231446A patent/AU2005231446A1/en not_active Abandoned
- 2005-04-01 CN CNA2005800121147A patent/CN1946399A/zh active Pending
- 2005-04-01 TW TW094110410A patent/TW200602040A/zh unknown
- 2005-04-01 BR BRPI0509512-3A patent/BRPI0509512A/pt not_active IP Right Cessation
- 2005-04-01 CA CA002561162A patent/CA2561162A1/en not_active Abandoned
- 2005-04-01 WO PCT/US2005/011107 patent/WO2005097122A2/en not_active Ceased
- 2005-04-01 DE DE602005017373T patent/DE602005017373D1/de not_active Expired - Lifetime
- 2005-04-01 DK DK05732721.5T patent/DK1734959T3/da active
-
2006
- 2006-09-18 IL IL178168A patent/IL178168A0/en unknown
- 2006-09-29 US US11/536,808 patent/US20070129403A1/en not_active Abandoned
-
2009
- 2009-07-17 CL CL2009001605A patent/CL2009001605A1/es unknown
-
2010
- 2010-01-11 CY CY20101100028T patent/CY1109734T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GT200500063A (es) | 2005-10-14 |
| SI1734959T1 (sl) | 2010-02-26 |
| ATE446754T1 (de) | 2009-11-15 |
| PL1734959T3 (pl) | 2010-03-31 |
| US20070129403A1 (en) | 2007-06-07 |
| CY1109734T1 (el) | 2014-09-10 |
| CN1946399A (zh) | 2007-04-11 |
| EP1734959A2 (en) | 2006-12-27 |
| ES2334241T3 (es) | 2010-03-08 |
| IL178168A0 (en) | 2006-12-31 |
| CA2561162A1 (en) | 2005-10-20 |
| DOP2005000050A (es) | 2005-11-30 |
| WO2005097122A2 (en) | 2005-10-20 |
| EP2138176A1 (en) | 2009-12-30 |
| MXPA06011222A (es) | 2007-01-16 |
| PA8628601A1 (es) | 2006-05-16 |
| PT1734959E (pt) | 2009-12-24 |
| JP2007531730A (ja) | 2007-11-08 |
| AU2005231446A1 (en) | 2005-10-20 |
| WO2005097122A3 (en) | 2006-02-02 |
| EP1734959B1 (en) | 2009-10-28 |
| SV2006002069A (es) | 2006-05-24 |
| TW200602040A (en) | 2006-01-16 |
| CL2009001605A1 (es) | 2009-11-27 |
| KR20070010161A (ko) | 2007-01-22 |
| DK1734959T3 (da) | 2010-03-08 |
| BRPI0509512A (pt) | 2007-09-11 |
| AR048197A1 (es) | 2006-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE489955T1 (de) | Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten | |
| DE602007006479D1 (de) | Verfahren und vorrichtungen zur behandlung von mehreren bohrlochintervallen | |
| DE602005017373D1 (de) | Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten | |
| EP1626730A4 (en) | METHOD, DEVICE AND COMPOSITION FOR TREATING ACNE | |
| ATE515261T1 (de) | Zusammensetzungen zur behandlung von diabetes | |
| ATE554091T1 (de) | Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes | |
| DE602006019560D1 (de) | 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen | |
| ATE496911T3 (de) | Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten | |
| EP1742675A4 (en) | TREATMENT OF BIOMEDICAL WASTE | |
| ATE509615T1 (de) | Verfahren und zusammensetzungen zur verhütung und/oder zur behandlung von empfindlicher und/oder trockener haut | |
| DE602006006354D1 (de) | Pinolensäure zur Behandlung von Übergewicht | |
| EP2049140A4 (en) | BOX AND METHODS FOR TREATING AN INTERVERTEBRAL DISC | |
| EP2069391A4 (en) | COMPOSITIONS AND METHODS FOR TREATING AND / OR PREVENTING OPHTHALMOLOGICAL DISEASES | |
| DE502005010499D1 (de) | Implantat zur Behandlung von Fettsucht | |
| DE602006003538D1 (de) | Benzothiazol-, thiazolopyridin-, benzooxazol- und oxazolopyridin-derivate als verbindungen zur behandlung von diabetes | |
| DE602006020201D1 (de) | Aerobes-anaerobes Verfahren zur Behandlung von organisch belasteten Abwässern | |
| EP1635801A4 (en) | METHODS OF TREATMENT AND PREVENTION OF CARDIAC ARRHYTHMIA | |
| EP1786465A4 (en) | METHODS FOR DETECTION AND TREATMENT OF AUTOIMMUNE DISORDERS | |
| DE602004021435D1 (de) | Injizierbare zusammensetzung zur behandlung von krebs | |
| ATE328880T1 (de) | Tetrazolderivate und verfahren zur behandlung von stoffwechselbedingten erkrankungen damit | |
| EP1905452A4 (en) | AGENT FOR THE PREVENTION OR TREATMENT OF GLAUCOMA | |
| EP1684735A4 (en) | COMPOUNDS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIAC ARRHYTHMIES INDUCED BY PHYSICAL EXERCISE | |
| DE602005023452D1 (de) | Mit calcitriol und clobetasolpropionat zur behandlung von schuppenflechte | |
| EP1888106A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH EPRININ SIGNALING USING CUPREDOXINS | |
| DE602006021192D1 (de) | Visnadin zur Behandlung von Kopfhautjucken |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |